PRA Health Sciences (PRAH)

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On June 15, 2021, PRA Health Sciences, Inc. (“PRA”) held a special meeting of its stockholders (the “Special Meeting”). As of the close of business on April 26, 2021, the record date for the Special Meeting, 64,795,400 shares of common stock, $0.01 par value per share, of PRA (the “PRA Common Stock”), were outstanding and entitled to vote. A total of 52,801,348 shares of PRA Common Stock were voted in person or by proxy, representing approximately 81.48% of the shares entitled to be voted, which constituted a quorum to conduct business at the Special Meeting. The following are the final voting results on proposals considered and voted upon at the Special Meeting, all of which are described in PRA’s Joint Proxy Statement/Prospectus, which was filed with the U.S. Securities and Exchange Commission on April 28, 2021.

Each of the proposals was approved by the requisite vote of PRA’s stockholders.

Proposal 1 — To adopt the Agreement and Plan of Merger, dated as of February 24, 2021, by and among ICON plc (“ICON”), PRA Health Sciences, Inc. (“PRA”), ICON US Holdings Inc., a wholly owned subsidiary of ICON (“US HoldCo”), and Indigo Merger Sub, Inc., a wholly owned subsidiary of ICON and US HoldCo (such agreement, as it may be amended from time to time, the “merger agreement” and such proposal, the “PRA merger agreement proposal”).

PRA’s stockholders approved the PRA merger agreement proposal.


Proposal 2 — To approve, on an advisory (non-binding) basis, the executive officer compensation that will or may be paid to PRA’s named executive officers that is based on or otherwise relates to the transactions contemplated by the merger agreement (the “PRA compensation proposal”).

PRA’s stockholders approved the PRA compensation proposal.


Proposal 3 — To approve the adjournment of the PRA stockholder meeting to solicit additional proxies if there are not sufficient votes at the time of the PRA stockholder meeting to approve the PRA merger agreement proposal or to ensure that any supplement or amendment to the accompanying joint proxy statement/prospectus is timely provided to PRA stockholders (the “PRA adjournment proposal”).

PRA’s stockholders approved the PRA adjournment proposal, if necessary, but an adjournment was not necessary in light of adoption of the merger agreement.